Benzingaยท2025-09-17 07:40Core Viewpoint - Martin Shkreli, known as 'Pharma Bro,' has taken a short position against Opendoor Technologies Inc. at a price of $9.36 and plans to conduct a public due diligence campaign on the company [1][2][3]. Group 1: Shkreli's Actions and Intentions - Shkreli's short position marks his first trade in Opendoor, and he intends to conduct diligence calls with various stakeholders, including former employees and competitors [2][3]. - He has publicly labeled Opendoor as "an obvious short" and has warned investors against holding long positions in the stock [4]. - Shkreli draws parallels between Opendoor and his previous successful short call against Newegg Commerce Inc., suggesting he anticipates a similar decline for Opendoor [4][5]. Group 2: Market Context and Reactions - Opendoor's stock has seen significant volatility, having risen over 1,000% from its 52-week lows, which has led to its classification as a "meme stock" [5]. - On the day of Shkreli's announcement, Opendoor's stock fell 6.06% to $8.92 per share, although it has advanced 461.01% year-to-date [7]. - Other short-sellers, such as Andrew Left of Citron Research, have also expressed bearish views on Opendoor, describing it as "a science project in how to burn money" [5].